11/ 13/ 2026
China Q3 Guideline for Topical Generics: What Changes
China's CDE issued a new Q3 characterization guideline for topically acting chemical generics on September 30, 2026, covering ten attributes plus sampling requirements and evaluation standards, effective immediately on publication.
11/ 13/ 2026
China Market Exclusivity for Rare Disease & Pediatric Drugs
NMPA proposes market exclusivity for rare disease drugs at seven, five or four years, and for pediatric drugs at two or one year, with comments open until 18 November 2026.
10/ 29/ 2026
China Pharma Plan 2026-2030: Innovation and Global Reach
China published its 15th Five-Year Plan for the pharmaceutical industry on 18 September 2026, setting ten 2030 targets and 25 key tasks on innovation, resilient supply chains and international expansion.
